AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24556773 — intervention group
Group type: COMPARATOR
Intervention: Heavy work demands
Number of subjects: 133
Study 22539562 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC (paclitaxel/carboplatin/epirubicin; 75 mg/m2 i.v.)
Number of subjects: 887
Study 22539562 — intervention group
Group type: COMPARATOR
Intervention: TC (paclitaxel/carboplatin; AUC 5 and 175 mg/m2)
Number of subjects: 887
Study 22539562 — intervention group
Group type: EXPERIMENTAL
Intervention: TEC
Number of subjects: 887
Study 22539562 — intervention group
Group type: COMPARATOR
Intervention: TC
Number of subjects: 887
Study 20181996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min of walking (exercise)
Number of subjects: 0
Study 20181996 — intervention group
Group type: COMPARATOR
Intervention: Sitting quietly (control)
Number of subjects: 0
Study 17616446 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-related T2s
Number of subjects: 55
Study 17616446 — intervention group
Group type: COMPARATOR
Intervention: Neutral T2s
Number of subjects: 55
Study 15616084 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of morphine
Number of subjects: 65
Study 15616084 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mL of saline (control group)
Number of subjects: 65
Study 11874412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg CRH
Number of subjects: 13
Study 11874412 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg CRH
Number of subjects: 13
Study 11874412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10360204 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine (HYZ) 3.7 mg/kg
Number of subjects: 30
Study 10360204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (HYZ) 3.7 mg/kg + Metoclopramide (MTP) 5 mg
Number of subjects: 30
Study 10360204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (HYZ) + Metoclopramide (MTP)
Number of subjects: 30
Study 7865500 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatment with the anticholinergic biperiden
Number of subjects: 31
Study 7865500 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 31
Study 7865500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1827005 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg or 2.5 mg twice daily orally for one year
Number of subjects: 23
Study 1827005 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 23
Study 1827005 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine with beta-blocker bopindolol
Number of subjects: 23
Study 6808225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (neomycin, colistin, and nystatin) in conventional ward isolation
Number of subjects: 0
Study 6808225 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict isolation, filtered air, sterilized food and oral antibiotics
Number of subjects: 0
Study 6808225 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial suppression but conventional ward isolation
Number of subjects: 0
Study 6808225 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for gut flora suppression in conventional ward isolation
Number of subjects: 0
Study 31090746 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-sinus implants without simultaneous bone grafting (group 1, n = 16)
Number of subjects: 32
Study 31090746 — intervention group
Group type: COMPARATOR
Intervention: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2, n = 16)
Number of subjects: 32
Study 31090746 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-sinus implants without simultaneous bone grafting (group 1)
Number of subjects: 32
Study 31090746 — intervention group
Group type: COMPARATOR
Intervention: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2)
Number of subjects: 32
Study 28294200 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants
Number of subjects: 42
Study 28294200 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants
Number of subjects: 42
Study 28294200 — intervention group
Group type: COMPARATOR
Intervention: Maxilla implants
Number of subjects: 42
Study 28294200 — intervention group
Group type: COMPARATOR
Intervention: Mandible implants
Number of subjects: 42
Study 28294200 — intervention group
Group type: COMPARATOR
Intervention: Immediate and delayed implants
Number of subjects: 42
Study 28294200 — intervention group
Group type: COMPARATOR
Intervention: Mandibular implants
Number of subjects: 42
Study 25882325 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2 mg
Number of subjects: 0
Study 25882325 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 4 mg
Number of subjects: 0
Study 25882325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24461797 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington's disease participants
Number of subjects: 11
Study 24461797 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 11
Study 24461797 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington's disease participants and matched controls
Number of subjects: 11
Study 22836511 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-pegylated liposomal doxorubicin (CD)
Number of subjects: 976
Study 22836511 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (CP)
Number of subjects: 976
Study 20961738 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotensive anaesthesia
Number of subjects: 60
Study 20961738 — intervention group
Group type: COMPARATOR
Intervention: Normotensive anaesthesia
Number of subjects: 60
Study 20961738 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotensive anaesthesia combined with isovolaemic haemodilution
Number of subjects: 60
Study 17514539 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 kcal/day free‐snack program
Number of subjects: 32
Study 17514539 — intervention group
Group type: COMPARATOR
Intervention: 1,500 kcal/day restricted‐snack program
Number of subjects: 32
Study 15886837 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and teeth brushing with YAHAO toothpaste (eugenol and borax cream)
Number of subjects: 48
Study 15886837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 11964594 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing oxygen with Pao2 increased to 406 +/- 47 mmHg
Number of subjects: 31
Study 11964594 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air at hemoglobin concentration of 5.7 +/- 0.3 g/dl
Number of subjects: 31
Study 11964594 — intervention group
Group type: COMPARATOR
Intervention: Control tests without alteration of hemoglobin concentration
Number of subjects: 31
Study 10213010 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (350 mg/m2 every 3 weeks)
Number of subjects: 267
Study 10213010 — intervention group
Group type: COMPARATOR
Intervention: infusional 5-FU
Number of subjects: 267
Study 10213010 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 267
Study 8545528 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO)
Number of subjects: 4
Study 8545528 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 4
Study 8545528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZP)
Number of subjects: 4
Study 8545528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tryptophan drink (Lo-TRP)
Number of subjects: 4
Study 8545528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 1693204 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR mode (activity responsive rate variable ventricular pacing)
Number of subjects: 14
Study 1693204 — intervention group
Group type: COMPARATOR
Intervention: DDD mode (dual chamber pacing at 80 beats/min)
Number of subjects: 14
Study 1693204 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR mode
Number of subjects: 14
Study 1693204 — intervention group
Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 14
Study 7018853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CFX)
Number of subjects: 18
Study 7018853 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 18
Study 31514054 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic benzodiazepine users (n = 47)
Number of subjects: 268
Study 31514054 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (n = 221)
Number of subjects: 268
Study 31514054 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting BZDs
Number of subjects: 268
Study 31514054 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting BZDs
Number of subjects: 268
Study 28849804 — intervention group
Group type: EXPERIMENTAL
Intervention: SonicFill (Kerr) with single-component self-etch adhesive system
Number of subjects: 30
Study 28849804 — intervention group
Group type: COMPARATOR
Intervention: Incrementally placed conventional posterior composite resin (Herculite Ultra, Kerr)
Number of subjects: 30
Study 26489051 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary blend of ancient peat and apple extracts (TRT)
Number of subjects: 25
Study 26489051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 25
Study 23379651 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) with metformin
Number of subjects: 165
Study 23379651 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH with metformin
Number of subjects: 165
Study 23379651 — intervention group
Group type: COMPARATOR
Intervention: rFSH only (Control group)
Number of subjects: 165
Study 17933162 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg x kg(‐1) caudal morphine
Number of subjects: 135
Study 17933162 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg x kg(‐1) caudal morphine
Number of subjects: 135
Study 17933162 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg x kg(‐1) caudal morphine
Number of subjects: 135
Study 14729792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 60
Study 14729792 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 60
Study 10740331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg piperazine oestrone sulphate + 0.7 mg norethisterone (highEP)
Number of subjects: 200
Study 10740331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg piperazine oestrone sulphate + 0.35 mg norethisterone (lowEP)
Number of subjects: 200
Study 10740331 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐oestradiol continuously combined with 1 mg norethisterone acetate (E2+NETA)
Number of subjects: 200
Study 10740331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10740331 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormone groups (highEP, lowEP, E2+NETA)
Number of subjects: 200
Study 9360156 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartPak Portable Pneumatic Driver
Number of subjects: 7
Study 9360156 — intervention group
Group type: COMPARATOR
Intervention: HeartMate 1000 (conventional driver)
Number of subjects: 7
Study 8472696 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (5.0 ml.kg‐1 body weight of a 19.7% carbohydrate drink)
Number of subjects: 10
Study 8472696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8472696 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink and Placebo
Number of subjects: 10
Study 3816096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16
Study 3816096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30970442 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI plus alginate (combination)
Number of subjects: 0
Study 30970442 — intervention group
Group type: COMPARATOR
Intervention: PPI only
Number of subjects: 0
Study 30970442 — intervention group
Group type: COMPARATOR
Intervention: Alginate only (reference group)
Number of subjects: 0
Study 26909669 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 5429
Study 26909669 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg daily
Number of subjects: 5429
Study 26909669 — intervention group
Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 5429
Study 26377199 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT of malaria at 3-month intervals using sulfadoxine-pyrimethamine and amodiaquine (n=127)
Number of subjects: 629
Study 26377199 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified complementary food (CF-FeFum) with 2 mg iron as NaFeEDTA and 3.8 mg iron as ferrous fumarate 6 days per week (n=126)
Number of subjects: 629
Study 26377199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CF-FeFum and IPT (n=124)
Number of subjects: 629
Study 26377199 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of porridge, an iron-fortified CF with the composition currently on the Ivorian market (CF-FePP) providing 2 mg iron as NaFeEDTA and 3.8 mg iron as ferric pyrophosphate 6 days per week (n=127)
Number of subjects: 629
Study 26377199 — intervention group
Group type: COMPARATOR
Intervention: Normal diet and IPT-placebo (n=125)
Number of subjects: 629
Study 24279701 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 1184
Study 24279701 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1184
Study 24279701 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA presence
Number of subjects: 1184
Study 21410682 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 21410682 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 19660489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg
Number of subjects: 12
Study 19660489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 12
Study 19660489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Number of subjects: 12
Study 19660489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16714498 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential registration in a screened area
Number of subjects: 302
Study 16714498 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard registration)
Number of subjects: 302
Study 15365540 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA‐AQ)
Number of subjects: 215
Study 15365540 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 215
Study 15365540 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF)
Number of subjects: 215
Study 11418354 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating interferon dose (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months; escalated to 9 MU at 6 weeks if HCV RNA detectable at 4 weeks)
Number of subjects: 63
Study 11418354 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months)
Number of subjects: 63
Study 9545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 10.0 mg/kg
Number of subjects: 24
Study 9545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 21.4 mg/kg
Number of subjects: 24
Study 9545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 40.0 mg/kg
Number of subjects: 24
Study 9545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP)
Number of subjects: 24
Study 8393638 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1 mg twice per day (n = 7)
Number of subjects: 15
Study 8393638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 15
Study 3540504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 0.36 mg daily
Number of subjects: 0
Study 3540504 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRO) 160 mg daily
Number of subjects: 0
Study 3540504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 70 mg daily
Number of subjects: 0
Study 3540504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27216984 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 65
Study 27216984 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intention intervention
Number of subjects: 65
Study 27216984 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 27216984 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions combined
Number of subjects: 65
Study 26711179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ergocalciferol (vitamin D2)
Number of subjects: 158
Study 26711179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 24706268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannequin training and video feedback
Number of subjects: 36
Study 24706268 — intervention group
Group type: COMPARATOR
Intervention: Mannequin training
Number of subjects: 36
Study 21852389 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver + 24 mg betahistine 2 times daily for 1 week
Number of subjects: 72
Study 21852389 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver + placebo 2 times daily for 1 week
Number of subjects: 72
Study 21852389 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver only
Number of subjects: 72
Study 19592234 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of liver metastases
Number of subjects: 0
Study 19592234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapies
Number of subjects: 0
Study 17598071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 47
Study 17598071 — intervention group
Group type: COMPARATOR
Intervention: Previous AEDs
Number of subjects: 47
Study 15946283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus plain ice
Number of subjects: 67
Study 15946283 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus flavoured ice
Number of subjects: 67
Study 15946283 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 67
Study 14551301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranodal (IN) administration of peptide-pulsed DC vaccines
Number of subjects: 27
Study 14551301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) administration of peptide-pulsed DC vaccines
Number of subjects: 27
Study 14551301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of peptide-pulsed DC vaccines
Number of subjects: 27
Study 10539100 — intervention group
Group type: EXPERIMENTAL
Intervention: First tube
Number of subjects: 95
Study 10539100 — intervention group
Group type: COMPARATOR
Intervention: Second tube
Number of subjects: 95
Study 8879440 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet (whole-food test diets)
Number of subjects: 33
Study 8879440 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 33
Study 1813067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosol protein content (4.15 mg/ml cut-off)
Number of subjects: 382
Study 1813067 — intervention group
Group type: COMPARATOR
Intervention: Protein-poor group
Number of subjects: 382
Study 1813067 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich group
Number of subjects: 382
Study 1813067 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein category
Number of subjects: 382
Study 6337769 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (200 mg)
Number of subjects: 24
Study 6337769 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (80 mg daily) with indomethacin (150 mg daily)
Number of subjects: 24
Study 6337769 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (300 mg) with indomethacin (150 mg daily)
Number of subjects: 24
Study 6337769 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg) with indomethacin (150 mg daily)
Number of subjects: 24
Study 6337769 — intervention group
Group type: COMPARATOR
Intervention: Triamterene (200 mg) with indomethacin (150 mg daily)
Number of subjects: 24
Study 6337769 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (given to 12 subjects)
Number of subjects: 24
Study 31943506 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Number of subjects: 474
Study 31943506 — intervention group
Group type: COMPARATOR
Intervention: 6-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Number of subjects: 474
Study 31241539 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAS insole with participant's own athletic footwear
Number of subjects: 15
Study 31241539 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participant's own athletic footwear)
Number of subjects: 15
Study 27054503 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based instructor-led mindfulness intervention
Number of subjects: 118
Study 27054503 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 118
Study 26876083 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG guided transfusion strategy
Number of subjects: 60
Study 26876083 — intervention group
Group type: COMPARATOR
Intervention: Standard management group
Number of subjects: 60
Study 24617494 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 271
Study 24617494 — intervention group
Group type: COMPARATOR
Intervention: Best Practice Care (BPC)
Number of subjects: 271
Study 21982425 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2706
Study 21982425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2706
Study 19148946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 8
Study 19148946 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 8